Application of pharmaceutical composition containing resveratrol and / or rabdosin in preparation of medicine for preventing or treating African swine fever

By using pharmaceutical compositions of resveratrol and lydecaline, inhibiting ASFV replication has been solved, and the problem of undetermined efficacy and safety of ASFV vaccines has been provided, providing a new antiviral drug that significantly improves the inhibition rate and safety of ASFV. , fills the gap in the prior art.

CN118873530APending Publication Date: 2024-11-01SHENYANG VICA BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410746699.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-11
Publication Date
2024-11-01

AI Technical Summary

Technical Problem

The long-term efficacy and safety of the existing African swine fever virus (ASFV) vaccine has not been determined, the cross-protection capacity needs to be further evaluated, and the research on antiviral drugs for ASFV infection is limited, resulting in insufficient methods for preventing and controlling ASF.

Method used

Develop pharmaceutical compositions containing resveratrol and/or lydecaprol for the preparation of the prevention or treatment of African swine fever by adjusting the weight ratio range of resveratrol and lydecaprol in the pharmaceutical composition (1:20 to 20:1) to inhibit ASFV replication and add the drug to pig feed for use.

Benefits of technology

Resveratrol and lydecaprolin showed significant anti-ASFV activity, with good safety and effectiveness, and could effectively inhibit ASFV replication, providing a new drug choice for preventing and controlling ASF, filling the gap in the existing technology. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118873530A_ABST
    Figure CN118873530A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of veterinary drugs, and particularly relates to application of a pharmaceutical composition in preparation of drugs for preventing or treating African swine fever. The pharmaceutical composition is prepared from resveratrol and / or rabdoline. On the basis of a traditional Chinese medicine monomer library composed of 100 natural small molecule drugs, the small molecule drugs with antiviral activity are screened on primary porcine alveolar macrophages, the selection indexes of rabdoline and resveratrol are the highest, it is indicated that the safety and effectiveness of the drug are the best when the drug is used for resisting the African swine fever virus, and the drug has good anti-viral activity on the primary porcine alveolar macrophages. Good application prospects are realized in the aspect of preventing and controlling African swine fever virus infection.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of veterinary drugs, and in particular relates to use of a pharmaceutical composition comprising resveratrol and / or linderpine in preparing a drug for preventing or treating African swine fever. Background Art

[0002] African swine fever virus (ASFV) is the only member of the genus Asfivirus in the family Asfarviridae and the only arbovirus-borne DNA virus. Its genome is 170-194 kb long and contains 151-167 open reading frames (ORFs). The differences in genome length and gene number are mainly caused by the gain or loss of ORFs in the multigene family encoded by the virus; while some smaller length changes are caused by differences in the number of short tandem repeats within or between genes. Based on the genetic evolution analysis of the p72 gene, 24 ASFV genotypes have been identified.

[0005] As more and more countries are affected by ASF, the prevention and control of ASF is imminent. ASF vaccine research has also made some significant progress. ASFV-G-ΔI177L can effectively inhibit the parent strain ASFV-G, and the vaccine has been commercialized in Vietnam. However, its long-term efficacy and safety have not yet been determined, and the cross-protection ability of the vaccine also needs further evaluation. The availability of cell lines and the optimization conditions of vaccines remain key constraints in the development of ASFV vaccines. Therefore, new methods for the prevention and control of ASF need to be sought. Studies have shown that small molecule compounds such as genkwain, genistein and nocodazole can inhibit ASFV replication, but in-depth research on antiviral drugs for ASFV infection is limited. Therefore, large-scale screening of anti-ASFV drugs is very necessary and urgent. The development of safe and effective antiviral drugs will help prevent and control the outbreak and spread of ASF. Summary of the invention

[0006] In order to solve the above technical problems, the present invention provides use of a pharmaceutical composition comprising resveratrol and / or linderpine in preparing a drug for preventing or treating African swine fever.

[0007] Specifically, the present invention is realized through the following technical solutions:

[0008] The present invention provides use of a pharmaceutical composition in preparing a drug for preventing or treating African swine fever, wherein the pharmaceutical composition comprises resveratrol and / or linderpine.

[0009] As an optional mode, in the above use, when the pharmaceutical composition comprises resveratrol and linderpine, the weight ratio of the resveratrol to the linderpine ranges from 1:20 to 20:1.

[0010] Preferably, the weight ratio of the resveratrol to the linderpine is in the range of 1:10 to 10:1.

[0011] More preferably, the weight ratio of the resveratrol to the linderpine is in the range of 1:5 to 5:1.

[0012] More preferably, the weight ratio of the resveratrol to the linderpine is in the range of 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1 or 5:1.

[0013] As an optional mode, in the above use, the resveratrol and / or linderpine inhibit the replication of African swine fever virus.

[0014] Optionally, the resveratrol and / or linderpine inhibit the replication of wild-type African swine fever virus or inhibit the replication of gene-deficient African swine fever virus.

[0015] Optionally, the gene-deficient African swine fever virus is ASFV-HLJ / 2018-ΔCD2v or ASFV-HLJ / 2018-ΔMGF / CD2v.

[0016] As an optional mode, in the above-mentioned use, the medicine comprises the pharmaceutical composition according to claim 1 and veterinary acceptable excipients.

[0017] As an optional mode, in the above-mentioned use, the dosage form of the drug is powder, oral solution or granules.

[0018] As an optional mode, in the above-mentioned use, when used for preventing or treating African swine fever, the drug is added to pig feed.

[0019] Compared with the prior art, the present invention has the following beneficial effects:

[0020] Based on a traditional Chinese medicine monomer library consisting of 100 natural small molecule drugs, the inventors screened small molecule drugs with antiviral activity on primary porcine alveolar macrophages. Among them, linderpine and resveratrol had the highest selection index, indicating that they had the best safety and effectiveness against ASFV, and may have good application prospects in the prevention and control of ASFV. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 : The results of the determination of the activity of PAM cells with different concentrations of DMSO.

[0022] Figure 2:The selection results of positive control concentration in the screening method. Among them, A. The effect of different concentrations of 3-AP on PAM cell viability. B. The inhibition rate of different concentrations of 3-AP on ASFV.

[0023] Figure 3 :The results of the determination of ASFV infection dose and infection time in the screening method. A. The calculation results of the Z factor at different times. B. The results of calculating the positive and negative control ratio at different times

[0024] Figure 4 :Results of screening of Chinese medicine monomer library. A. Results of primary screening. B. Results of observation of cell status of drugs with inhibition rate ≥ 50%. C. Results of secondary screening.

[0025] Figure 5 :The results of the effects of 4 candidate drugs on PAM cell viability. A. The effect of resveratrol on PAM cell viability. B. The effect of lingdecaline on PAM cell viability. C. The effect of luteolin on PAM cell viability. D. The effect of aescin XVII on PAM cell viability.

[0026] Figure 6 :The inhibition results of 4 candidate drugs at different mass concentrations on ASFV replication. A. The effect of resveratrol on ASFV replication. B. The effect of lingdecaline on ASFV replication. C. The effect of luteolin on ASFV replication. D. The effect of aescin XVII on ASFV replication.

[0027] Figure 7 :The results of two candidate drugs inhibiting ASFV-WT replication. A. Virus genome copy number determination results. B. Virus titer determination results

[0028] Figure 8 :The results of two candidate drugs inhibiting the replication of ASFV with different gene deletions. A. The results of ASFV-HLJ / 2018-ΔCD2v viral genome copy number corresponding to resveratrol and lingderatine. B. The results of ASFV-HLJ / 2018-ΔCD2v viral titer corresponding to resveratrol and lingderatine. C. The results of ASFV-HLJ / 2018-ΔMGF / CD2v viral genome copy number corresponding to resveratrol and lingderatine. D. The results of ASFV-HLJ / 2018-ΔMGF / CD2v viral titer corresponding to resveratrol and lingderatine. DETAILED DESCRIPTION

[0029] The present invention will be further described with reference to specific embodiments below. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the scope of the present invention.

[0030] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.

[0031] The experimental methods in the following examples are conventional methods unless otherwise specified. The experimental materials used in the following examples are commercially available products unless otherwise specified.

[0032] 1 Materials and methods

[0033] 1.1 Drugs and reagents

[0034] The Chinese medicine monomer library was constructed by Shenyang Weijia Biotechnology Co., Ltd.; RPMI-1640 medium and penicillin-streptomycin (double antibody) were purchased from Gibco; fetal bovine serum (FBS) was purchased from Inner Mongolia Aopsai Biotechnology Co., Ltd.; nucleic acid DNA / RNA extraction kits were purchased from Hangzhou Biori Technology Co., Ltd.; qPCR related reagents were purchased from TaKaRa; The luminescent cell viability assay (ad) was purchased from Promega; the Hoechst33342 live cell staining solution (100X) was purchased from Bio-Time.

[0035] 1.2 Cells and virus strains

[0036] The PAM cells used in this study were obtained from bronchial lavage of specific pathogen-free (SPF) pigs; the wild-type ASFV was HLJ / 2018 (ASFV-WT) (GenBank accession number: MK333180.1) and was preserved in the inventor's laboratory; the strain used in this study to screen small molecule drugs was an ASFV reporter virus expressing red fluorescent protein (mRuby) (ASFV-HLJ / 2018-CD2v / mRuby), which was based on HLJ / 2018 as the backbone, and mRuby was inserted into the C-terminus of the CD2v gene. The recombinant virus was purified and had the same growth curve as the HLJ / 2018 strain and no difference in replication kinetics. In addition, ASFV-HLJ / 2018-ΔCD2v and ASFV-HLJ / 2018-ΔMGF / CD2v were both gene-deficient viruses constructed by the inventor's laboratory, and compared with the parental virus, the growth curve was consistent and the replication kinetics were no different.

[0037] 1.3 Establishment of antiviral drug library screening method

[0038] 1.3.1 Determination of the effect of dimethyl sulfoxide on PAM cell viability

[0039] PAM is converted to 10 5Cells / well were added to a 96-well cell culture plate at 100 μL / well. After the cells were completely attached, dimethyl sulfoxide (DMSO) with concentrations of 0.02%, 0.05%, 0.1%, 0.2%, 0.5%, 1% and 2% were added to the 96-well cell culture plate at 100 μL / well. Each concentration was repeated 3 wells. Cell culture medium was added to the control wells at 100 μL / well. There were no cells in the blank wells, and an equal volume of cell culture medium was added. The cell culture plate was placed in an incubator and cultured for 48 hours. After discarding the cell supernatant, 100 μL / well of CellTiter-Glo reagent was added, shaken and mixed for 2 minutes, the cells were lysed, and incubated at room temperature in the dark for 10 minutes. The luminescence value was detected using an enzyme reader, and the cell viability under different concentrations of DMSO treatment was calculated.

[0040] 1.3.2 Selection of positive control concentration in high-throughput screening system

[0041] The experiment was carried out according to the method in 1.3.1. The concentrations of the M2 subunit inhibitor of ribonucleotide reductase (3-AP) were 1, 2.5 and 5 μM, and the corresponding DMSO concentrations were 0.01%, 0.025% and 0.05%, respectively. After the experiment, the cell survival rate at each concentration was calculated. 5 100 μL / well of the cells were added to a 96-well cell culture plate. After the cells were completely attached, 3-AP with final concentrations of 1, 2.5 and 5 μM were mixed with ASFV-HLJ / 2018-CD2v / mRuby with a multiplicity of infection (MOI) of 1.5, and added to the 96-well cell culture plate. Three replicate wells were added for each concentration, and a control was set up. The cell culture plate was placed in an incubator and cultured for 24 hours. The inhibition rate of different concentrations of 3-AP on ASFV-HLJ / 2018-CD2v / mRuby was calculated using a fluorescence imaging system.

[0042] 1.3.3 Determination of infection dose and infection time of ASFV-HLJ / 2018-CD2v / mRuby in high-throughput screening system

[0043] 10 5 Cells / well were plated in 96-well cell culture plates and cultured for about 12 hours. 5μM 3-AP was mixed with 0.2, 0.5, 1 and 1.5 MOI of ASFV-HLJ / 2018-CD2v / mRuby and inoculated into cells. Negative controls were set up at the same time. Samples were fixed at 24h, 36h and 48h after infection and detected with a high-throughput live cell analysis system. The Z factor has become the main parameter for evaluating the quality of test methods, and it has also been proven to be one of the effective ways to evaluate test methods in statistical methods.

[0044] 1.4 High-throughput screening of Chinese medicine monomer library

[0045] PAM is converted to 10 5 Cells / well were plated on a 96-well cell culture plate, 100 μL / well. After the cells were placed in the incubator, they were waited for about 12 hours until the cells were completely attached. The small molecule drug with a final concentration of 10 mg / L was mixed with ASFV-HLJ / 2018-CD2v / mRuby (MOI=1.5) and added to the cell culture plate, 100 μL / well. The negative control was treated without small molecule drugs and the cells were infected with ASFV-HLJ / 2018-CD2v / mRuby; the positive control was treated with 3-AP (5 μM) and the cells were infected with ASFV-HLJ / 2018-CD2v / mRuby; the blank control was neither treated with small molecule drugs nor infected with ASFV-HLJ / 2018-CD2v / mRuby, and was placed in the incubator for 24 hours. The culture medium was discarded, 4% paraformaldehyde fixative (100 μL / well) was added, fixed at room temperature for 30 minutes, the fixative was discarded, phosphate buffer (PBS) was added at 100 μL / well, washed 3 times, 0.3% triton X-100 (100 μL / well) was added, permeabilized at room temperature for 15-30 minutes, 0.3% triton X-100 was discarded, and PBS was added at 100 μL / well for washing 3 times. Hoechst diluted 1:100 was added at 100 μL / well and incubated at room temperature in the dark for 10 minutes. After discarding Hoechst, it was washed 3 times with PBS, and finally PBS (100 μL / well) was added for high-throughput screening. The cell number and virus fluorescence number were analyzed using Zeiss image analysis software (ZEN2.3), and the inhibition rate of small molecule drugs on ASFV-HLJ / 2018-CD2v / mRuby replication was calculated.

[0046] 1.5 Determination of the activity of small molecule drugs on PAM cells

[0047] PAM cells (10 5 100 mg / L) were plated in a 96-well cell culture plate, and four candidate drugs, resveratrol, rinderine, luteolin and gypenoside XVII, were added to the 96-well cell culture plate at mass concentrations of 2, 5, 10, 20, 50 and 100 mg / L, respectively. Three replicate wells were set for each concentration, and a control was set. The detection was performed according to the method in 1.3.1, and the cell viability and half cytotoxicity concentration (CC) under different drug concentrations were calculated. 50 ).

[0048] 1.6 IC of small molecule drugs against ASFV-HLJ / 2018-CD2v / mRuby 50 Determination

[0049] PAM cells (5×10 5 / well) were spread on a 24-well cell culture plate, and the cells were placed in an incubator until the cells were completely attached. Four candidate drugs with final concentrations of 0.01, 0.1, 1, 2, 5 and 10 mg / L were mixed with ASFV-HLJ / 2018-CD2v / mRuby (MOI = 1.5), and added to the cell culture plate, 500 μL / well, and positive and negative controls were set at the same time. They were placed in an incubator and cultured for 24 hours, and the cell supernatant and precipitate were collected to detect the number of viral genome copies, and the effect of the candidate drugs against ASFV infection was evaluated, and the half inhibitory concentration (50% maximal inhibitory concentration, IC 50 ).

[0050] 1.7 Viral genome extraction

[0051] ASFV genomic DNA was extracted using an automatic nucleic acid extractor and a matching viral nucleic acid extraction kit, and the ASFV viral genome copy number was determined by targeting the p72 gene.

[0052] 1.8 Virus titer determination

[0053] PAMs were cultured in 96-well cell culture plates (5×10 4 The virus was diluted 10-fold, and 100 μL of the diluted virus solution was inoculated in a 96-well cell culture plate. Eight replicate wells were set for each dilution. A control group was also set up and cultured at 37°C and 5% CO2 for 5 days. The number of positive wells in the 96-well cell culture plate was observed and recorded using an inverted fluorescence microscope. The 50% tissue culture infectious dose (TCID 50 ).

[0054] 1.9 Effects of small molecule drugs on wild-type ASFV replication

[0055] PAM cells (5×10 5 After the cells adhered to the wall, resveratrol and linderpine at a final concentration of 10 mg / L were mixed with ASFV-WT (MOI = 1.5), respectively, and then added to the cell culture plate, 500 μL / well, and positive and negative controls were set up at the same time. The cells were cultured in an incubator for 24 hours, and the cell supernatant and precipitate were collected to detect the viral genome copy number and virus titer.

[0056] 1.10 Inhibitory effects of small molecule drugs on ASFV strains with different gene deletions

[0057] PAMs were cultured in 24-well plates (5 × 10 5 / well), ASFV-HLJ / 2018-ΔCD2v and ASFV-HLJ / 2018-ΔMGF / CD2v with MOI=1.5 were mixed with resveratrol and lingdeline at a final concentration of 10 mg / L, respectively, and added to the cell culture plate, 500 μL / well, and positive and negative controls were set at the same time. The plates were placed in an incubator and cultured for 24 hours, and the cell supernatant and precipitate were collected to detect the viral genome copy number and virus titer.

[0058] 1.11 Biosafety Statement

[0059] All experiments involving the manipulation of live ASFV viruses were conducted in the BLS3 biosafety laboratory of the Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences.

[0060] 1.12 Statistical analysis

[0061] The results were analyzed statistically using GraphPad Prism 8.0. ns, P ≥ 0.05 indicated no significant difference; *, P < 0.05 and **, P < 0.01 indicated significant difference; ***, P < 0.001 and ****, P < 0.0001 indicated extremely significant difference.

[0062] 2 Results

[0063] 2.1 Establishment of antiviral drug library screening method

[0064] 2.1.1 Determination of the effect of dimethyl sulfoxide on PAM cell viability

[0065] When the DMSO concentration was ≤0.2%, there was no significant difference in cell viability compared with the negative control, indicating that it did not affect the viability of PAM cells; when the DMSO concentration was ≥0.5%, there was a very significant difference in cell viability compared with the negative control, indicating that it had a significant toxic effect on PAM cells ( Figure 1 ). Therefore, the concentration of DMSO used as a solvent in subsequent screening of the Chinese medicine monomer library should be ≤0.2%.

[0066] 2.1.2 Selection of positive control concentration in screening method

[0067] After adding 3-AP at final concentrations of 1, 2.5 and 5 μM to PAM cells and culturing for 24 h, the effects of the three concentrations of 3-AP on PAM cell viability were not significantly different from those of the negative control ( Figure 2A); 3-AP with a final concentration of 1, 2.5 and 5 μM was mixed with ASFV-HLJ / 2018-CD2v / mRuby and added to PAM cells for 24 hours. The images were taken using a high-throughput live cell analysis system and the cell number and virus fluorescence number were analyzed using Zeiss image analysis software (ZEN2.3). The ratio was calculated and it was found that 5 μM 3-AP had the highest inhibition rate on the virus, and the inhibition rate was higher than 90% ( Figure 2 B). Therefore, the concentration of the positive control 3-AP was selected as 5 μM in subsequent experiments.

[0068] 2.1.3 Determination of ASFV infection dose and infection time in screening methods

[0069] The Z factor is a combination of signal range and variation, and has become the main parameter for evaluating the quality of the detection method. The value of the Z factor can be calculated according to the formula: (σ = standard deviation, p = positive control, n = negative control, μ = mean value), where the Z factor value is between 0.5-1 for the best. Figure 3 As shown in A, when MOI = 1.5, the Z factors at 24h, 36h and 48h are all between 0.5-1, indicating that the optimal infection dose is MOI = 1.5; the ratio of positive and negative controls is the largest at 24h, indicating that the optimal infection time is 24h ( Figure 3 B).

[0070] 2.2 High-throughput screening of small molecule drugs that inhibit ASFV replication

[0071] This study used the high-throughput screening technology platform established above to conduct rapid initial screening of 100 small molecule drugs in the Chinese medicine monomer library. Each screening plate contained negative control wells, positive control wells, and blank control wells. The remaining cell wells were used as sample wells, and 3 replicate wells were set up. 24 hours after ASFV infection, we used a high-throughput live cell analysis system to take images and used Zeiss image analysis software (ZEN2.3) to analyze the cell number and virus fluorescence number, and calculated the percentage of ASFV replication inhibition in the test group wells. Figure 4 A shows that there are 12 drugs with an inhibition rate of ≥50%. We further observed the cell status and found that compared with normal cells, only 5 drugs corresponding to PAM cells did not collapse or shrink, and were in a normal state ( Figure 4 B), and further rescreened the five drugs in a dose-dependent manner (the final drug concentrations were 1:500, 1:1000, 1:2000, and 1:5000, respectively). The cell count and virus fluorescence count were analyzed using Zeiss image analysis software (ZEN2.3) to calculate the inhibition rate. The results showed that only four candidate drugs (2114: resveratrol, 8513: linderpine, 3177: luteolin, and 563: aescin XVII) showed obvious dose-dependency, such as Figure 4 As shown in C.

[0072] 2.34 small molecule drugs to determine the activity of PAM cells

[0073] The cytotoxicity of resveratrol, linderpine, luteolin and esculin XVII to PAM was determined using CellTiter-Glo reagent. Figure 5 As shown in the figure, when the mass concentration of resveratrol, luteolin and aescin XVII is ≤10mg / L, there is almost no effect on the viability of PAM cells; while when the mass concentration of lingderline is ≤20mg / L, there is almost no effect on the viability of PAM cells. 50 They are 35.81, 230.30, 14.20 and 27.62 mg / L respectively.

[0074] 2. Determination of the effects of 44 small molecule drugs on ASFV replication

[0075] Four candidate drugs with final concentrations of 0.01, 0.1, 1, 2, 5 and 10 mg / L were mixed with ASFV-HLJ / 2018-CD2v / mRuby to infect cells for 24 hours, and the cell supernatant and precipitate were collected to detect the number of viral genome copies. The results showed that with the increase in the mass concentration of the four candidate drugs, the number of ASFV genome copies decreased significantly. The IC values ​​of resveratrol, lingderline, luteolin and esculin XVII were calculated. 50 0.24, 1.15, 0.77 and 3.63 mg / L respectively ( Figure 6 ).

[0076] 2.5 Determination of selection index

[0077] Selection index (SI) is an important indicator for evaluating the safety and efficacy of small molecule drugs in vitro. The larger the SI, the higher the safety and efficacy of the small molecule drug. The calculation formula of SI is: SI = CC 50 / IC 50 According to the results of 2.3 and 2.4, we calculated the SI of resveratrol, linguine, luteolin and esculin XVII, among which linguine had the highest SI, followed by resveratrol (Table 1), indicating that these two drugs have high potential as antiviral drugs and can be further studied.

[0078] Table 1 SI determination results of 4 drug candidates

[0079]

[0080] Effects of 52 small molecule drugs on the replication of wild-type ASFV

[0081] Resveratrol and lingdeline at a final concentration of 10 mg / L were mixed with ASFV-WT to infect cells for 24 hours, and the cell supernatant and precipitate were collected to detect the viral genome copy number and virus titer. The results showed that with the increase of drug mass concentration, the ASFV genome copy number and virus titer decreased significantly ( Figure 7 A. Figure 7 B), indicating that both resveratrol and linderpine can significantly inhibit the replication of ASFV-WT.

[0082] 2. Inhibitory effects of 62 small molecule drugs on ASFV strains with different gene deletions

[0083] Resveratrol and lingdecanol with a final concentration of 10 mg / L were mixed with ASFV-HLJ / 2018-ΔCD2v and ASFV-HLJ / 2018-ΔMGF / CD2v to infect cells for 24 hours, and the cell supernatant and precipitate were collected to detect the viral genome copy number and virus titer. The results showed that both small molecule drugs could inhibit the replication of ASFV strains with different gene deletions to varying degrees ( Figure 8 ).

[0084] 3 Discussions

[0085] ASFV causes severe and fatal hemorrhagic diseases in domestic pigs and wild boars, and the mortality rate of infected pigs can be as high as 100%. At present, the prevention and control of ASF mainly relies on early rapid detection and culling of infected pigs. Due to the complex structure of ASFV, the long genome, and the complex immune escape mechanism, little is known about ASFV protective immunity at this stage. Although various vaccines against ASFV have made varying degrees of progress, safe and effective ASFV vaccines have not yet been developed in China. A large number of clinical trials and tests are still needed to evaluate their reliability, and the research and development cycle is long, which forces us to seek new ways to prevent and control ASFV. Safe and effective antiviral drugs can provide protection in the event of an outbreak, thereby helping to curb the spread of the epidemic and buying more time for farmers to find countermeasures. Therefore, it is particularly urgent to develop antiviral drugs for ASFV.

[0086] In the process of evaluating the anti-ASFV effect of small molecule drugs, some plant-active drugs have the characteristics of low cost, small side effects and good efficacy, showing good anti-ASFV application prospects. For example, genistein extracted from soybeans may act as an ATP competitive inhibitor to play an anti-ASFV role in ASFV infection; genkwain can significantly inhibit the infection of ASFV during the virus invasion and release stages by blocking the microtubule movement of ASFV; natural polyphenol compound dodecyl gallate mainly acts on the early infection stage of ASFV, inhibiting membrane fusion during virus adsorption and affecting its entry into the cell, thus playing an anti-ASFV role.

[0087] High-throughput screening is one of the strategies for selecting drugs with good effects in small molecule drug design. By establishing efficient and fast experimental methods and screening models, drugs with specific biological activities can be discovered, the success rate of drug research and development can be improved, and drugs can be moved from laboratory research to clinical application.

[0088] In this study, a high-throughput screening method for anti-ASFV drugs was established. First, the infected cells were divided into experimental and control groups according to the drug treatment methods for a certain period of time. After the infected cells were fixed, the fluorescence signal was read using a high-throughput live cell analysis system. Then, the cell number and virus fluorescence number were analyzed using Zeiss image analysis software (ZEN2.3) to calculate the drug inhibition rate. The advantages of this method are that it is easy to operate and the relevant experimental technology is mature. Compared with using a single or multiple viral proteins as targets, this study used ASFV live virus to infect cells for screening. Compared with using a single or multiple viral proteins as targets, the false positive rate of detection was greatly reduced, and the accuracy was higher, thereby enhancing the reliability and persuasiveness of the test results. In the subsequent research of the drug, this method can also be used as a fast and simple means of drug evaluation. Through simple calculations, the inhibition rate of different drug concentrations can be obtained, and nonlinear fitting can be performed to obtain the IC of the drug. 50 , in order to effectively evaluate the antiviral effect of the drug. The high-throughput screening method for anti-ASFV drugs established in this study can quickly screen and evaluate small molecule drugs with anti-ASFV activity, providing researchers with an effective screening tool and laying the foundation for the subsequent development of effective anti-ASFV drugs. The resveratrol and lingdecaine screened in this study have an inhibition rate of more than 90% on ASFV, and the SI of the two is relatively high, which has high potential as anti-ASFV drugs.

[0089] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.

Claims

1. Use of a pharmaceutical composition in the preparation of a drug for preventing or treating African swine fever, characterized in that: The pharmaceutical composition comprises resveratrol and / or linderpine.

2. The use according to claim 1, characterized in that: When the pharmaceutical composition comprises resveratrol and linguine, the weight ratio of the resveratrol to the linguine ranges from 1:20 to 20:

1.

3. The use according to claim 2, characterized in that: The weight ratio of the resveratrol to the linderpine is in the range of 1:10 to 10:

1.

4. The use according to claim 3, characterized in that: The weight ratio of the resveratrol to the linderpine is in the range of 1:5 to 5:

1.

5. The use according to claim 1, characterized in that: The resveratrol and / or linderpine inhibit the replication of African swine fever virus.

6. The use according to claim 5, characterized in that: The resveratrol and / or linderpine inhibit the replication of wild-type African swine fever virus or inhibit the replication of gene-deficient African swine fever virus.

7. The use according to claim 5, characterized in that: The gene-deficient African swine fever virus is ASFV-HLJ / 2018-ΔCD2v or ASFV-HLJ / 2018-ΔMGF / CD2v.

8. The use according to claim 1, characterized in that: The medicine comprises the pharmaceutical composition according to claim 1 and veterinary acceptable excipients.

9. The use according to claim 1, characterized in that: The dosage form of the medicine is powder, oral solution or granules.

10. The use according to claim 1, characterized in that: When used to prevent or treat African swine fever, the drug is added to pig feed.